Last 70.00 NGN
Change Today 0.00 / 0.00%
Volume 166.5K
As of 9:30 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline consumer nig (GLAXOSMI) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/4/14 - 71.44
52 Week Low
05/14/13 - 47.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

glaxosmithkline consumer nig (GLAXOSMI) Related Businessweek News

No Related Businessweek News Found

glaxosmithkline consumer nig (GLAXOSMI) Details

GlaxoSmithKline Consumer Nigeria Plc manufactures, markets, and distributes consumer healthcare and pharmaceutical products in Nigeria. The company operates in two segments, Pharmaceuticals and Consumer Healthcare. It offers consumer healthcare products, including oral care products, OTC medicines, and nutritional health care products primarily under the Panadol, Andrews Liver Salt, Macleans, Sensodyne, Phensic, Lucozade, and Ribena brands; and pharmaceutical products comprising prescription drugs and vaccines principally under the Ampiclox, Amoxil and Augmentin Antibiotics, Zentel, and Halfan brands. GlaxoSmithKline Consumer Nigeria Plc provides its pharmaceutical products for the treatment of asthma, malaria, depression, migraine, diabetes, heart failure, digestive conditions, and cancer; and vaccines to protect against illnesses, such as hepatitis A and B, diphtheria, tetanus, whooping cough, typhoid, influenza, and cervical cancer. The company, formerly known as Beecham Limited, was incorporated in 1971 and is headquartered in Lagos, Nigeria. GlaxoSmithKline Consumer Nigeria Plc is a subsidiary of GlaxoSmithKline Plc, the United Kingdom.

Founded in 1971

glaxosmithkline consumer nig (GLAXOSMI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

glaxosmithkline consumer nig (GLAXOSMI) Key Developments

GlaxoSmithKline Consumer Nigeria Plc Announces Management Changes

GlaxoSmithKline Consumer Nigeria Plc has announced the appointment of an interim Managing Director, Justin Korteasa following the voluntary resignation of Mr. Chidi Okoro, as the company's Managing Director with effect from March 15, 2014. Until a new candidate is confirmed for the role, the GSK Nigeria Board has appointed Mr. Justin Korte as a Director and the General Manager. Korte joined GSK from Gillette in early 2005, and has progressed through national accounts and national sales roles. After running his own business in 2008, Justin returned to head GSK's Southern Africa business as Group Country Manager. He was promoted in 2011 to Sales Director, Africa.

GlaxoSmithKline To Continue With Its Plan To Acquire Nigerian Unit

GlaxoSmithKline plc (LSE:GSK) may continue with its plans to acquire a majority stake in its Nigerian unit after suspending the plan four months ago. Chidi Okoro, Chief Executive Officer of GlaxoSmithKline Consumer Nigeria Plc (NGSE:GLAXOSMITH), said that the plan by GSK to increase equity in its Nigerian unit was only suspended and will come up later when all parties involved reach an agreement. Chidi said, "Our focus is that if it has to be done, it's done right." GSK, in July 2013, proposed to raise its stake in the Nigerian business to 80% from 46.4%, in a transaction estimated at $98 million.

GlaxoSmithKline Consumer Nigeria plc Announces Earnings Results for the First Quarter Ended March 31, 2012; Announces Impairments for the First Quarter Ended March 31, 2012; Declares First Interim Dividend Payable on July 5, 2012

GlaxoSmithKline Consumer Nigeria plc announced earnings results for the first quarter ended March 31, 2012. For the quarter, the company's core operating profit was GBP 2,071 million, a 3% increase in CER terms on a turnover increase of 2% reflecting improved operating leverage. Total operating profit was GBP 2,037 million compared with GBP 2,035 million in 2011. The net cash inflow from operating activities for the period was GBP 1,012 million against GBP 987 million a year ago. Turnover was GBP 6,640 million against GBP 6,585 million a year ago. Profit before taxation was GBP 1,879 million against GBP 2,464 million a year ago. Profit attributable to shareholders was GBP 1,325 million or GBP 26.3 pence per diluted share against GBP 1,525 million or GBP 29.6 pence per diluted share a year ago. Purchase of property, plant and equipment was GBP 168 million against GBP 175 million a year ago. Core profit before taxation was GBP 1,913 million against GBP 1,889 million a year ago. Core profit attributable to shareholders was GBP 1,353 million or GBP 27.3 per share against GBP 1,316 million or GBP 25.9 per share a year ago. For the quarter, the company also announced intangible impairments of GBP 52 million against GBP 8 million a year ago. The board has declared a first interim dividend of 17 pence per share against 16 pence per share a year ago. The equivalent interim dividend receivable by ADR holders is 54.9100 cents per ADS based on an exchange rate of GBP 1/$1.6150. The ex-dividend date will be May 9, 2012, with a record date of May 11, 2012 and a payment date of July 5, 2012.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLAXOSMI:NL 70.00 NGN 0.00

GLAXOSMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $16.09 USD +0.02
AstraZeneca PLC 3,782 GBp +23.00
Dainippon Sumitomo Pharma Co Ltd ¥1,593 JPY +20.00
Merck & Co Inc $56.47 USD +0.21
Teva Pharmaceutical Industries Ltd $50.85 USD +0.94
View Industry Companies

Industry Analysis


Industry Average

Valuation GLAXOSMI Industry Range
Price/Earnings 21.6x
Price/Sales 8.6x
Price/Book 20.3x
Price/Cash Flow 21.6x
TEV/Sales 2.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE CONSUMER NIG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at